search
Back to results

Phase 1 Study to Evaluate Safety and Pharmacokinetics of FZJ-003 in Healthy Volunteers

Primary Purpose

Healthy Volunteers

Status
Recruiting
Phase
Phase 1
Locations
China
Study Type
Interventional
Intervention
FZJ-003
Placebo
Sponsored by
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Healthy Volunteers

Eligibility Criteria

18 Years - 50 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  1. Written informed consent;
  2. Communicate well with the researcher and be able to complete the research in accordance with the research regulations;
  3. No plan for pregnancy in the next 6 months and voluntarily take effective contraceptive measures; No plan for sperm or egg donation;
  4. Healthy male and/or female subjects between the ages of 18 and 50 years ( inclusive);
  5. Male body weight≥50.0kg or female body weight≥45.0kg; Body Mass Index (BMI) between 18 to 28 (both inclusive), calculated as weight in kg / height in m2.

Exclusion Criteria:

  1. Someone smoking more than 5 pieces per day within the 3 months before the trial;
  2. Suspected of being allergic to investigational drug or any ingredient in the investigational drug, or people with allergies (multi-drug or food allergies);
  3. Having a history of alcohol abuse (14 units of alcohol per week: 1 units = beer 285 mL, or 25 mL of spirits, or 100 mL of wine);
  4. Blood donation or extensive blood loss ≥400 mL within 3 months before screening, or planning blood donors during the study;
  5. Urine drug test positive or have a history of drug abuse or drug use in the past 5 years;
  6. Subjects who were intolerant of high-fat meals (2 boiled eggs, 1 slices of buttered bacon toast, a box of fries, and a glass of whole milk) were applied only to subjects who participated in the postprandial test;
  7. Taked any drug within 14 days before screening, including prescription drugs, over-the-counter drugs, Chinese herbal medicines and health products (except regular supplementary vitamins);
  8. Taked any drug that changes liver drug enzyme activity within 28 days before screening, such as CYP3A4 inhibitors or inducers;
  9. Major changes in diet or exercise habits within 2 weeks before screening or during the period from screening to administration;
  10. Took a special diet (including dragon fruit, mango, grapefruit, etc.) or strenuous exercise, and other activities that affect drug absorption, distribution, metabolism, excretion and so on within 2 weeks before screening;
  11. Received or planned to receive any vaccine within 30 days before and after the trial;
  12. Participated in clinical trials within 3 months before the first administration of the study, or planned to participate in other clinical trials during the study period;
  13. Having difficulty of swallowing or any history of gastrointestinal diseases that affect drug absorption;
  14. With low immune function or immunodeficiency, or long-term use of immunosuppressive drugs; or used immunosuppressive drugs within 30 days before screeing;
  15. Have or have had malignant tumors;
  16. Active tuberculosis; or have a history of tuberculosis or latent tuberculosis infection; tuberculosis infection T cell spot test positive;
  17. Any infection that has been determined to be clinically significant by the investigator within 3 months or any infection within 7 days before the study;
  18. Herpes or varicella within 3 months before the trial;
  19. Underwent major trauma or major surgery in 3 months before screening, or have plan for surgery in trial;
  20. Have a history of diverticulitis, peptic ulcer or perforation of digestive tract;
  21. Clinical laboratory tests are abnormal and have clinical significance, or other clinical findings showing clinically significant diseases (including but not limited to heart Cerebrovascular, gastrointestinal, lungs, endocrine, renal, nerves, blood, immunizations, or mental disease);
  22. Active viral hepatitis (B or C) as demonstrated by positive serology at Screening;or test positive for human immunodeficiency virus (HIV) at Screening; or syphilis treponema pallidum antibody and syphilis rapid plasma reagin test are positive;
  23. QTcB interval greater than (>) 470 (male) or 480 (female) milliseconds;
  24. Female subjects are in lactation or serum pregnancy test are positive during screening or during the test;
  25. Acute illness or combination therapy from the screening stage to administration;
  26. Taking chocolate, any caffeine, or xanthine-rich food or drink at least 48 hours prior to the use of the study drug;
  27. Taking any alcoholic products within 24 hours prior to the use of the study drug, or cannot limit alcohol drinks as required in trial;
  28. Other circumstances that is deemed not appropriate for the trial.

Sites / Locations

  • the First Bethune Hospital of Jilin UniversityRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

FZJ-003

Placebo

Arm Description

Outcomes

Primary Outcome Measures

Adverse events and the number of volunteers with adverse events as a measure of safety and tolerability
Tests will be performed to assess whether the study drug has any potentially adverse effect (laboratory tests on blood and urine for functioning of organs; ECG testing). Also, participants will carefully be monitored by medical staff for vital signs, and asked to report any side effect experienced in the course of the study.

Secondary Outcome Measures

Maximum Plasma Concentration (Cmax)
Area under the plasma concentration-time curve (AUC)
Pharmacodynamics (PD) parameters of percent and actual change from baseline for a panel of JAK-dependent biomarkers

Full Information

First Posted
January 19, 2021
Last Updated
March 15, 2022
Sponsor
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
search

1. Study Identification

Unique Protocol Identification Number
NCT04715529
Brief Title
Phase 1 Study to Evaluate Safety and Pharmacokinetics of FZJ-003 in Healthy Volunteers
Official Title
A Phase 1, Randomized, Double-blind, Placebo-controlled, Dose-escalation and Food Effect Study to Assess the Safety, Tolerance, and Pharmacokinetics of FZJ-003 In Healthy Volunteers
Study Type
Interventional

2. Study Status

Record Verification Date
March 2022
Overall Recruitment Status
Recruiting
Study Start Date
January 27, 2021 (Actual)
Primary Completion Date
May 31, 2023 (Anticipated)
Study Completion Date
June 30, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
A randomized, double-blinding, dose-escalated phase 1 trial to evaluate the tolerance and fasting/postprandial pharmacokinetics of FZJ-003, an oral Janus kinase1 (JAK1) inhibitor.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Healthy Volunteers

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Model Description
SAD and MAD: 6 cohorts, 8 subjects take FZJ-003 and 2 subjects take placebo; Food Effect on Phamocokinetics: 14 subjects, crossover designing
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
62 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
FZJ-003
Arm Type
Experimental
Arm Title
Placebo
Arm Type
Placebo Comparator
Intervention Type
Drug
Intervention Name(s)
FZJ-003
Intervention Description
Subjects will receive FZJ-003 oral capsules in a dose escalation format.
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Subjects will receive placebo oral capsules (matching FZJ-003) in a dose escalation format .
Primary Outcome Measure Information:
Title
Adverse events and the number of volunteers with adverse events as a measure of safety and tolerability
Description
Tests will be performed to assess whether the study drug has any potentially adverse effect (laboratory tests on blood and urine for functioning of organs; ECG testing). Also, participants will carefully be monitored by medical staff for vital signs, and asked to report any side effect experienced in the course of the study.
Time Frame
up to 72 hours postdose
Secondary Outcome Measure Information:
Title
Maximum Plasma Concentration (Cmax)
Time Frame
up to 72 hours postdose
Title
Area under the plasma concentration-time curve (AUC)
Time Frame
up to 72 hours postdose
Title
Pharmacodynamics (PD) parameters of percent and actual change from baseline for a panel of JAK-dependent biomarkers
Time Frame
up to 24 hours postdose

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Written informed consent; Communicate well with the researcher and be able to complete the research in accordance with the research regulations; No plan for pregnancy in the next 6 months and voluntarily take effective contraceptive measures; No plan for sperm or egg donation; Healthy male and/or female subjects between the ages of 18 and 50 years ( inclusive); Male body weight≥50.0kg or female body weight≥45.0kg; Body Mass Index (BMI) between 18 to 28 (both inclusive), calculated as weight in kg / height in m2. Exclusion Criteria: Someone smoking more than 5 pieces per day within the 3 months before the trial; Suspected of being allergic to investigational drug or any ingredient in the investigational drug, or people with allergies (multi-drug or food allergies); Having a history of alcohol abuse (14 units of alcohol per week: 1 units = beer 285 mL, or 25 mL of spirits, or 100 mL of wine); Blood donation or extensive blood loss ≥400 mL within 3 months before screening, or planning blood donors during the study; Urine drug test positive or have a history of drug abuse or drug use in the past 5 years; Subjects who were intolerant of high-fat meals (2 boiled eggs, 1 slices of buttered bacon toast, a box of fries, and a glass of whole milk) were applied only to subjects who participated in the postprandial test; Taked any drug within 14 days before screening, including prescription drugs, over-the-counter drugs, Chinese herbal medicines and health products (except regular supplementary vitamins); Taked any drug that changes liver drug enzyme activity within 28 days before screening, such as CYP3A4 inhibitors or inducers; Major changes in diet or exercise habits within 2 weeks before screening or during the period from screening to administration; Took a special diet (including dragon fruit, mango, grapefruit, etc.) or strenuous exercise, and other activities that affect drug absorption, distribution, metabolism, excretion and so on within 2 weeks before screening; Received or planned to receive any vaccine within 30 days before and after the trial; Participated in clinical trials within 3 months before the first administration of the study, or planned to participate in other clinical trials during the study period; Having difficulty of swallowing or any history of gastrointestinal diseases that affect drug absorption; With low immune function or immunodeficiency, or long-term use of immunosuppressive drugs; or used immunosuppressive drugs within 30 days before screeing; Have or have had malignant tumors; Active tuberculosis; or have a history of tuberculosis or latent tuberculosis infection; tuberculosis infection T cell spot test positive; Any infection that has been determined to be clinically significant by the investigator within 3 months or any infection within 7 days before the study; Herpes or varicella within 3 months before the trial; Underwent major trauma or major surgery in 3 months before screening, or have plan for surgery in trial; Have a history of diverticulitis, peptic ulcer or perforation of digestive tract; Clinical laboratory tests are abnormal and have clinical significance, or other clinical findings showing clinically significant diseases (including but not limited to heart Cerebrovascular, gastrointestinal, lungs, endocrine, renal, nerves, blood, immunizations, or mental disease); Active viral hepatitis (B or C) as demonstrated by positive serology at Screening;or test positive for human immunodeficiency virus (HIV) at Screening; or syphilis treponema pallidum antibody and syphilis rapid plasma reagin test are positive; QTcB interval greater than (>) 470 (male) or 480 (female) milliseconds; Female subjects are in lactation or serum pregnancy test are positive during screening or during the test; Acute illness or combination therapy from the screening stage to administration; Taking chocolate, any caffeine, or xanthine-rich food or drink at least 48 hours prior to the use of the study drug; Taking any alcoholic products within 24 hours prior to the use of the study drug, or cannot limit alcohol drinks as required in trial; Other circumstances that is deemed not appropriate for the trial.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Yanhua Ding, MD
Phone
+86-0431-88782705
Email
dingyanhua2003@126.com
Facility Information:
Facility Name
the First Bethune Hospital of Jilin University
City
Changchun
State/Province
Jilin
ZIP/Postal Code
130000
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
LiYuan Zhao
Phone
+86 0431-88782013
Email
kjkzhaoliyuan@126.com

12. IPD Sharing Statement

Learn more about this trial

Phase 1 Study to Evaluate Safety and Pharmacokinetics of FZJ-003 in Healthy Volunteers

We'll reach out to this number within 24 hrs